PIK3CA and colorectal carcinoma: These findings implicate oncogenic PIK3CA mutations as a driver of glutamine dependence in CRC and suggest that targeting glutamine metabolism may represent a viable therapeutic strategy for patients harboring PIK3CA mutations (120).